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INTRODUCTION
Ductal carcinoma in situ (DCIS) is a preinvasive lesion that 
has increased in frequency of diagnosis with the extensive use 
of mammography for screening The rate of lymph node metas-
tasis in pure DCIS is extremely low (≤1%) [1-3] and the need 
for axillary lymph node dissection (ALND) for DCIS is generally 
believed to be unwarranted, although axillary lymph node status 
is the most important prognostic indicator in breast cancer.
Sentinel node biopsy is recommended for patients with inva-
sive breast cancer, although the role of sentinel node biopsy in 
DCIS is controversial [4,5]. The rates of positive sentinel node 
biopsy in patients with pure DCIS vary between 2% and 13% 
[1-3,6,7], and many studies suggest that sentinel node biopsy in 
pure DCIS can be safely avoided [8-10]. However, other studies 
reported that high-risk DCIS and DCIS with microinvasion 
(DCISM) are associated with a high incidence of lymph node 
micrometatasis [3,11-13].
Furthermore, most preoperative diagnoses of DCIS are       
diagnosed by core needle biopsy (CNB) which has a higher 
risk of invasive breast cancer on final pathologic diagnosis, 
and the reported rate of underestimation varies between 8.3% 
and 43.6% [14-17].
In this study, we evaluated whether sentinel node biopsy is 
required in patients with an initial diagnosis of DCIS and we 
focused on the rates of axillary node metastasis and the under-
estimation of invasive carcinoma at an initial diagnosis.
METHODS
A retrospective analysis was performed of 81 patients with 
an initial diagnosis of DCIS or DCISM at Daegu Catholic Uni-
versity Medical Center, who were reviewed from December 
2002 to April 2010.
The patients were diagnosed with DCIS preoperatively by 
either CNB or excision, except for one patient who was diag-
nosed by fine needle aspiration (FNA). CNB and FNA were 
performed under ultrasonography (USG) guidance in all cases. 
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Purpose: Axillary lymph node status is the strongest prognostic 
indicator of survival for women with breast cancer. The purpose 
of this study was to evaluate whether sentinel lymph node biopsy 
(SLNB) is required in patients with an initial diagnosis of ductal 
carcinoma in situ (DCIS). Methods: A retrospective analysis was 
performed of 78 patients with an initial diagnosis of DCIS between 
December 2002 and April 2010 and who proceeded to have either 
SLNB or axillary node dissection performed as part of their pri-
mary surgical procedure. The study focused on the rates of axil-
lary node metastasis and the underestimation of invasive carci-
noma at an initial diagnosis. Results: Forty-eight patients under-
went SLNB and 18 patients underwent axillary node dissection. 
Only 1 of 66 patients (1.5%) had a positive sentinel lymph node. 
After definite surgery, the final diagnosis was changed to inva-
sive ductal carcinoma (IDC) in 12 patients and DCIS with micro-
invasion in 2 patients; 14 of 78 patients (17.9%) were therefore 
underestimated at preoperative histological examinations. In 35 
patients who were diagnosed DCIS by core needle biopsy (CNB), 
13 patients (37.1%) were upstaged into IDC or DCIS with micro-
invasion in the final diagnosis. The statistically significant factors 
predictive of invasive breast cancer were a large tumor size and 
HER2 overexpression. Conclusion: The rates of SLNB positivity in 
pure DCIS are very low, and there is continuing uncertainty about 
its clinical importance. However in view of the high rate of under-
estimation of invasive carcinoma in patients with an initial diag-
nosis of DCIS, SLNB appears to be appropriate in these patients, 
especially in the case when DCIS is diagnosed by a core needle 
biopsy. In patients with an initial diagnosis of DCIS by CNB, SLNB 
should be considered as part of the primary surgical procedure, 
when preoperative variables show a tumor larger than 2.35 cm 
and with HER2 overexpression.
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The patients preoperatively underwent mammography, breast 
USG and FNAC of suspicious axillary lymph nodes. All patients 
underwent breast surgery such as breast conserving surgery or 
mastectomy, and sentinel lymph node biopsy (SLNB) or ALND 
was performed as part of their primary surgical procedure.
All surgical specimens and sentinel lymph nodes were ex-
amined histologically with hematoxylin and eosin (H&E) stain. 
If no metastasis was detected in the sentinel nodes (SNs) on 
H&E staining, they were evaluated using immunohistochemi-
cal (IHC) stain with cytokeratin (CAM 5.2; BD Biosciences, 
San Jose, USA). SNs were classified as either positive if they 
contained either macrometastases or micrometastases, or 
negative if only isolated tumor cells were present. Malignant 
cells in regional lymph nodes detected by H&E or IHC that 
were no greater than 0.2 mm were defined as pN0(i+), and no 
regional lymph node metastases histologically and negative 
IHC were defined as pN0(i-). The Van Nuys classification sys-
tem was used for grading the DCIS. Microinvasive disease was 
defined as tumor invading ≤1 mm, according to the seventh 
edition of the American Joint Committee on Cancer (AJCC) 
staging manual for breast cancer.
The clinicopathological characteristics such as age, meno-
pausal state, initial diagnostic method, operation method, 
whether the mass was palpable, microcalcification on mam-
mogram, and initial diagnostic method were evaluated based 
on medical records. Prognostic factors including whole tumor 
size, pathologic T stage, nodal status, nuclear grade, resection 
margin status, comedo necrosis, estrogen receptor (ER), pro-
gesterone receptor (PR), human epidermal growth factor recep-
tor 2 (HER2), Bcl-2, and Ki67 were evaluated. 
Patients were divided into two groups according to the con-
sistency between initial and final diagnosis. The underestimated 
group consisted of patients whose diagnosis was upgraded to 
invasive breast carcinoma or at least microinvasion in final diag-
nosis. The consistent group was defined as the patients whose 
final diagnosis was the same as initial diagnosis. 
The statistical analysis was performed using SPSS version 
15.0 (SPSS Inc., Chicago, USA). The correlation between the 
two groups and clinicopathological features was assessed by the 
chi-square test or Fisher’s exact test and student t-test. We cal-
culated the cut-off value of the significant continuous variable 
by calculating the area under (AUC) the receiver operating 
characteristic (ROC) curve. A p-value of less than 0.05 was 
considered statistically significant.
RESULTS
Clinicopathologic characteristics of the patients
The average age of the 78 patients with breast cancer was 
50.6±11.1 years (range, 32-81 years). All patients were female, 
38 (48.7%) were postmenopausal and 39 (50.0%) were premeno-
pausal. 
Of the 78 patients studied, 30 (38.5%) underwent breast 
conserving surgery, and 48 (61.5%) had mastectomy. Among 
the 66 (84.6%) patients who underwent axillary staging, nodal 
metastasis was present in only one patient who underwent 
SLNB, and she had no additional lymph node metastasis on 
axillary lymph node dissection. IHC stain of sentinel nodes 
showed pN0(i-) in all node-negative patients.
All grades and sizes of lesions were represented, although 
26 of the patients had comedocarcimona. Four patients had a 
focus of microinvasion (<1 mm) with an initial diagnosis of 
DCIS. All patients were within the resection margin-free state 
(margin distance greater than 1 cm) and none of the DCIS 
patients had lymphovascular invasion.
Table 1 shows the general characteristics of the patients; 45 
patients (57.7%) had microcalcification on mammogram and 
31 patients (39.7%) had palpable masses on physical examina-
tion. In particular, the patient with axillary metastasis, she has 
a palpable tumor about 2 cm in diameter without comedo   
necrosis and she underwent CNB as an initial diagnostic method. 
Thirty-five patients (44.9%) underwent CNB and 42 patients 
(53.8%) underwent excison biopsy as the initial diagnostic     
biopsy method.
Table 1. General patient characteristics 
Characteristics with 
   initial diagnosis of DCIS
Study patients,  
No. (%)  
(n=78)
Patient with  
axillary metastasis  
(n=1)
Age (yr)* 50.6±11.1 (32-81) 50
Menopausal state Postmenopausal
   Postmenopausal 38 (48.7)
   Premenopausal 39 (50.0)
Tumor size (mm)* 19.3±13.6 (1-60) 20
Nuclear grade Intermediate
   Low 20 (25.6)
   Intermediate 17 (21.8)
   High 14 (17.9)
Comedo necrosis 26 (33.3)
Microcalcifications 45 (57.7) No
Palpable mass 31 (39.7) Yes
Initial diagnostic method CNB
   CNB 35 (44.9)
   Excision 42 (53.8)
   FNA 1 (1.3)
Operation method BCS
   Mastectomy 48 (61.5)
   BCS 30 (38.5)
DCIS=ductal carcinoma in situ; CNB=core needle biopsy; FNA=fine needle 
aspiration; BCS=breast conserving surgery.
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Comparison between initial and final pathologic diagnosis
Eleven of the 35 patients (31.4%) with a CNB diagnosis of 
DCIS had invasive carcinoma in the surgical specimen, while 
patients with DCIS diagnosed by an excision biopsy as the initial 
diagnostic method had no invasive carcinoma in final diagnosis 
(Table 2).
Four patients had a CNB diagnosis of DCIS with areas of 
invasion <1 mm, amounting to DCISM. One of these patients 
(25%) had invasive carcinoma in the surgical specimen.
Of the 78 patients who had DCIS or DCISM initially, 17.9% 
overall were upgraded to invasive breast carcinoma or at least 
microinvasion in final diagnosis. 
Of the 35 patients who had DCIS in the CNB specimen, the 
rate of underestimation was relatively high at 37.1%.
Pathology review of initial DCIS for those patients with final 
invasive ductal carcinoma (IDC)
Of the 12 patients who were upgraded to the IDC in final 
diagnosis, 11 patients (91.7%) underwent CNB as initial diag-
nostic method (Table 3). In these patients, the mean size of whole 
tumor was 31.8±9.0 mm, but in most of these the size of inva-
sive tumor size was less than 2 cm (83.3%). Seven of the 12 pa-
tients (58.3%) had comedo necrosis.
Comparison between consistent group and underestimated 
group in initial diagnosis of DCIS
Compared with the consistent group between initial and     
final diagnosis, the underestimated group had more palpable 
masses (p=0.038) and a higher rate of CNB as the initial diag-
nostic method (p<0.001) (Table 4). Also, the underestimated 
group more frequently underwent mastectomy than consistent 
group (p=0.040). The underestimated group was statistically 
significantly associated tumor size, comedo necrosis, and ER 
status in univariate analysis (p<0.001, p=0.037, and p=0.023, 
respectively). No significant differences were seen in mean value 
of age, menopausal state, microcalcification on preoperative 
mammogram and nuclear grade between the two groups.
Univariate analysis of association of invasive breast cancer 
with clinicopathologic parameters in patients with an initial 
diagnosis of DCIS by CNB 
In patients with an initial diagnosis of DCIS by CNB, inva-
sive breast cancer was statistically associated with the mean size 
of whole tumor and HER2 overexpression (Table 5). Logistic 
regression analysis was performed to assess the independent 
association of invasive breast cancer with statistically significant 
predictive factors in univariate analysis. The odds ratios of sig-
nificant factors were 1.1 (95% confidence interval [CI], 1.0-1.2) 
and 0.3 (95% CI, 0.1-0.9) at tumor size and HER2 overexpres-
sion, respectively. We determined the ROC and AUC value 
for tumor size and based on the cut-off value of 2.35 cm, AUC 
Table 2. Comparison between initial and final pathologic diagnosis
Initial diagnosis
Final  
diagnosis
 No. (%)
Initial diagnostic method
CNB  
(n=35)
Excision  
(n=42)
FNA  
(n=1)
DCIS (n=74) IBC 11 (14.9) 11   0 0
DCISM 2 (2.7)   2   0 0
DCIS only 61 (82.4) 21 40 0
DCISM (n=4) IBC   1 (25.0)   0   0 1
DCISM   2 (50.0)   0   2 0
DCIS only   1 (25.0)   1   0 0
CNB=core needle biopsy; FNA=fine needle aspiration; DCIS=ductal carci-
noma in situ; IBC=invasive breast cancer; DCISM=ductal carcinoma in situ 
with microinvasion.
Table 3. Pathology review of initial DCIS for those patients with final invasive ductal carcinoma
Patient No. Initial Final
Tumor size*  
(mm)
T stage Nuclear grade Comedo necrosis
Initial diagnostic  
method
1 DCIS IDC 35 2 Intermediate Present CNB
2 DCIS IDC 20 1c Intermediate Absent CNB
3 DCIS IDC 25 1a Intermediate Absent CNB
4 DCISM IDC 35 2 High Absent FNA
5 DCIS IDC 38 1a High Absent CNB
6 DCIS IDC 18 1c Low Absent CNB
7 DCIS IDC 25 1a Intermediate Present CNB
8 DCIS IDC 30 1mi High Present CNB
9 DCIS IDC 40 1mi Low Present CNB
10 DCIS IDC 30 1mi Intermediate Present CNB
11 DCIS IDC 50 1a Intermediate Present CNB
12 DCIS IDC 35 1a Intermediate Present CNB
DCIS=ductal carcinoma in situ; IDC=invasive ductal carcinoma; CNB=core needle biopsy; DCISM=ductal carcinoma in situ with microinvasion; FNA=fine nee-
dle aspiration.
*Tumor size=whole tumor size including invasive foci.304  BokKyoungSon,etal.
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was 0.797, sensitivity was 84.6%, and specificity was 68.2%.
SLNB in patients with an initial diagnosis of DCIS by excision
We evaluated the results of SLNB in patients with an initial 
diagnosis of DCIS by excision. Among 40 patients with pure 
DCIS by excision, 15 patients underwent SLNB and nodal 
metastasis was not found at H&E stain nor IHC stain.
DISCUSSION
DCIS is diagnosed when a proliferation of cancerous cells 
within the mammary ductal-lobular system without invasion, 
and microscopically basement membrane is preserved. Accord-
ing to the definition, DCIS cells do not metastasize and DCIS 
is not a systemic disease, therefore the need for ALND for DCIS 
is generally believed to be unwarranted. However, several studies 
investigating lymph node status in patients with DCIS reported 
axillary lymph node metastasis in DCIS [1-3,6,7], and the role 
of ALND in patients with DCIS remains controversial.
SLNB is accepted as a standard axillary approach for clinically 
axillary negative breast cancer patients [4,5]. The technique is 
highly accurate with low false-negative rates and is associated 
with significantly lower morbidity than ALND [18,19]. Reported 
rates of positive SLNB results associated with pure DCIS vary 
between 2% and 13% [1-3,6,7]. Although most clinicians have 
abandoned the routine use of SLNB in all patients with DCIS, 
many still believe that there is a subset of patients at high risk 
for microinvasive disease and subsequent axillary metastasis 
who may benefit from the procedure [3,11-13]. In contrast, the 
present study has shown that the rate of lymph node metastases 
in patients with DCIS is extremely low and the results of SLNB 
in patients with pure DCIS by excision showed no lymph node 
metastasis. Therefore, on this basis, to recommend SLNB for 
patients with DCIS seems to be inappropriate.
However, several studies demonstrated that preoperative 
diagnoses of DCIS based on CNB are likely to be underesti-
mated. Rates of underestimated diagnosis range from 8.3% to 
43.6% [14-17], and in this study, the rate of underestimation 
in patients with a CNB diagnosis as initial diagnostic method 
was relatively high at 37.1%. It is well known that axillary lymph 
node status is the most important prognostic indicator of breast 
cancer, and subsequent lymph node dissection will be required 
Table 4. Comparison between consistent group and underestimated group in initial diagnosis of DCIS
Characteristics
Consistent group 
No. (%)
Underestimated group 
No. (%)
 OR (95% CI) p-value
Age (yr)* 50.6±11.5 50.6±9.1 0.992
Menopausal state 0.217
   Postmenopause 29 (46.0)   9 (64.3)
   Premenopause 34 (54.0)   5 (35.7)
Tumor size (mm)* 16.4±12.6 32.6±9.1 0.9 (0.8-1.0) <0.001
Nuclear grade 0.258
   Low 18 (47.4)   2 (15.4)
   Intermediate   9 (23.7)   8 (61.5)
   High 11 (28.9)   3 (23.1)
Comedo necrosis 18 (28.1)   8 (57.1)   3.4 (1.0-11.2) 0.037
ER 0.023
   Positive 45 (76.3)   6 (42.9) 0.2 (0.1-0.8)
   Negative 14 (23.7)   8 (57.1)
PR 0.112
   Positive 51 (86.4)   9 (64.3)
   Negative   8 (13.6)   5 (35.7)
Microcalifications on  mammogram 38 (59.4)   7 (50.0) 0.520
Palpable mass 22 (34.4)   9 (64.3)   3.4 (1.0-11.5) 0.038
Initial diagnostic method <0.001
   CNB 22 (34.4) 13 (92.9)
   Excision 42 (65.6) 0 (0.0)
   FNA 0 (0.0) 1 (7.1)
Operation method   4.7 (1.0-22.6) 0.040
   Mastectomy 36 (56.3) 12 (85.7)
   BCS 28 (43.8)   2 (14.3)
DCIS=ductal carcinoma in situ; OR=odds ratio; CI=confidence interval; ER=estrogen receptor; PR=progesterone receptor; CNB=core needle biopsy; FNA=fine 
needle aspiration; BCS=breast conserving surgery.
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when invasive disease is identified in the final pathology. Many 
surgeons have therefore recommend SLNB for patients with 
DCIS who undergo mastectomy because there is no opportu-
nity to perform lymphatic mapping after mastectomy if inva-
sive disease is identified in the breast on final pathology review. 
Although routine SLNB in all patients with DCISM is not war-
ranted, several authors have demonstrated that microinvasive 
disease raises the possibility of axillary metastases, and the 
lymph node metastases seen in final pathology may reflect the 
presence of small invasive lesions that went undetected in the 
tissue sampling process [20,21].
Because final histological type as invasive cancer was an im-
portant predictor of positive SNs, we also evaluated the clinico-
pathologic predictors of invasive cancer in patients with a pre-
operative diagnosis of DCIS or DCISM. Comparative analysis 
between the consistent group and the underestimated group in 
initial diagnosis of DCIS showed 6 independent predictors of 
underestimation in these patients: palpable masses on physical 
examination, CNB as the method of preoperative diagnosis, 
mastectomy as the operation method, mean size of whole tumor, 
comedo necrosis and ER status. The finding that larger DCIS 
size is more likely to be associated with invasive cancer is in 
agreement with the published literature [13,22,23]. In patients 
with DCIS, the presence of extensive calcification or of an asso-
ciated mass lesion at mammography suggests a greater likeli-
hood of an invasive component [24]. However in this study, 
invasive cancer was not significantly associated with the pres-
ence of microcalcification on mammogram. Some authors have 
Table 5. Univariate analysis of clinical and histopathological parameters in patients with an initial diagnosis of DCIS by core needle biopsy predictive of 
invasive breast cancer 
Characteristics
DCIS
No. (%)
Invasive cancer
No. (%)
OR (95% CI) p-value
Age (yr)* 54.5±13.0  51.0±9.4 0.359
Menopausal state 1.000
   Postmenoapuse 14 (63.6)   8 (61.5)
   Premenopause   8 (36.4)   5 (38.5)
Tumor size (mm)* 20.1±12.1 32.4±9.4 1.1 (1.0-1.2) 0.002
Nuclear grade 0.682
   Low   7 (36.8)   2 (16.7)
   Intermediate   7 (36.8)   8 (66.7)
   High   5 (26.3)   2 (16.7)
Comedo necrosis   7 (31.8)   8 (61.5) 0.086
Microcalifications on mammogram 13 (59.1)   7 (53.8) 0.762
Palpable mass 10 (45.5)   8 (61.5) 0.358
Op. method 0.116
   Mastectomy 13 (54.2) 11 (84.6)
   BCS   9 (40.9)   2 (15.4)
ER 0.157
   Positive 16 (72.7)   6 (46.2)
   Negative   6 (27.3)   7 (53.8)
PR 0.243
   Positive 18 (81.8)   8 (61.5)
   Negative   4 (18.2)   5 (38.5)
HER2 0.3 (0.1-0.9) 0.008
   Overexpression   8 (36.4) 10 (76.9)
   No overexpression   3 (13.6)   3 (23.1)
Bcl2 0.444
   Positive 17 (77.3)   8 (61.5)
   Negative   5 (22.7)   5 (38.5)
p53 0.689
   Positive 17 (77.3) 11 (84.6)
   Negative   5 (22.7)   2 (15.4)
Ki67 0.140
   ≥10% 15 (75.0) 10 (100.0)
   <10%   5 (25.0) 0 (0.0)
DCIS=ductal carcinoma in situ; OR=odds ratio; CI=confidence interval; Op.=operation; BCS=breast conserving surgery; ER=estrogen receptor; PR=progesterone 
receptor.
*Mean±SD.306  BokKyoungSon,etal.
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also reported that on multivariate analysis, patients diagnosed 
with DCIS or DCISM by CNB were at increased risk for inva-
sive cancer compared with patients diagnosed by excision biop-
sy [13,22,23], and our results are consistent with those previ-
ously reported.
Studies have attempted to quantify underestimation and to 
predict which DCIS lesions at CNB will show invasion at final 
excision histological examination [25-27]. In a meta-analysis 
of studies reporting cases of CNB diagnosis of DCIS and pre-
senting data on DCIS underestimates, preoperative variables 
significantly associated with understaging include biopsy device 
and guidance method, size, grade, mammographic features, 
and palpability [28]. In our study, significant factors predictive 
of invasive breast cancer in patients with an initial diagnosis of 
DCIS by CNB were tumor size and HER2 status. 
We analyzed the associated factors to a high underestimation 
rate of CNB. Obtaining a greater volume of tissue with larger 
gauge core biopsy reduces underestimation of invasive cancer 
[15]; limitations of sampling with a 14 gauge core biopsy device 
and inadequate sampling error therefore seemed to be one of 
the factors. Another important finding was that CNB has a much 
lower specificity for sampling distortions relative to other diag-
nostic methods [15], and that CNB does not discriminate well 
between invasive cancer and DCIS that have a lack of basement 
membrane at samples. Furthermore, most invasive cancer had 
invasive foci smaller than 5 mm in tumor in our data; thus the 
invasive component seemed to have been missed by CNB, result-
ing in underestimation. Some studies showed that the availability 
of USG guidance as an office procedure has increased the pre-
cision of the CNB considerably [28,29]. However, inadequacy 
is not significantly associated with guidance or core method in 
our data, since all lesions were sampled under USG guidance 
regardless of whether or not they were clinically palpable.
Our study has a few limitations, including the small cohort, 
possibility of missing cases of micrometastases or isolated tumor 
cells in sentinel nodes, and the absence of molecular study of 
sentinel nodes. Furthermore, we have not evaluated long-term 
follow-up information for our cohort. Despite these limitations, 
we believe that this study provides a valuable guide for physi-
cians who treat patients with an initial diagnosis of DCIS. With 
these limitations in mind, we conclude that SLNB in patients 
with an initial diagnosis of DCIS should be limited to patients 
who are planned to undergo mastectomy or who have a DCIS 
with palpable masses on physical examination, or whose mam-
mogram reveals microcalcification. Patients who have a CNB 
diagnosis of DCIS have a higher risk of invasive breast cancer 
on final pathologic assessment of the primary tumor; in these 
patients, SLNB should therefore be considered as part of their 
primary surgical procedure, especially in patients with tumor 
larger than 2.35 cm and HER2 overexpression.
In conclusion, we found that the rate of underestimation in 
patients with a CNB diagnosis as initial diagnostic method was 
37.1%. In view of the high rate of underestimation of invasive 
carcinoma in patients with a CNB diagnosis of DCIS in this 
study, SLNB appears to be warranted in this group of patients. 
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